17 January 2012 - US Amerigen Pharmaceuticals Ltd and Shanghai Fosun Omni Pharmaceutical Co Ltd said last week they have sealed an agreement for the development of generic oral controlled release products.

Under the deal, Fosun Omni will utilise its formulation expertise to develop products for Amerigen to commercialise in the US and other territories.

Fosun Omni received an up-front fee with respect to the first product and is eligible for additional product-specific development milestones and royalties on any commercialised products.